Invention Grant
- Patent Title: Compounds
-
Application No.: US17402802Application Date: 2021-08-16
-
Publication No.: US11958833B2Publication Date: 2024-04-16
- Inventor: Mark Ian Kemp , Martin Lee Stockley , Andrew Madin
- Applicant: MISSION THERAPEUTICS LIMITED
- Applicant Address: GB Cambridge
- Assignee: Mission Therapeutics Limited
- Current Assignee: Mission Therapeutics Limited
- Current Assignee Address: GB Cambridge
- Priority: GB 22267 2015.12.17
- Main IPC: C07C201/00
- IPC: C07C201/00 ; A61K31/4025 ; A61K31/407 ; A61K31/4725 ; A61P3/00 ; A61P3/10 ; A61P9/00 ; A61P19/02 ; A61P21/00 ; A61P25/00 ; A61P25/14 ; A61P25/16 ; A61P25/28 ; A61P35/00 ; A61P35/04 ; A61P43/00 ; C07D207/09 ; C07D401/12 ; C07D403/12 ; C07D403/14 ; C07D413/12 ; C07D417/12 ; C07D417/14 ; C07D471/04 ; C07D487/04

Abstract:
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the Invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
Public/Granted literature
- US20210380562A1 Novel Compounds Public/Granted day:2021-12-09
Information query